Search - tctmd.com

Displaying 361 - 380 of 431

Sort: Relevancy | Date

News Daily News

TAVR Use Triples in France, With Docs Treating Lower-Risk Patients

Michael O'Riordan

June 26, 2017

News Conference News TVT 2017

Merits of Minimalist TAVR: Patient Satisfaction and a Better Bottom Line

Michael O'Riordan

June 20, 2017

News Conference News TVT 2017

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Shelley Wood

June 16, 2017

News Conference News TVT 2017

Q&A: Transcatheter Valve Innovation Past, Present, and Future as TVT Turns 10

Shelley Wood

June 12, 2017

News Conference News EuroPCR 2017

TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years

Caitlin E. Cox

May 17, 2017

News Conference News EuroPCR 2017

Bicuspid AS Patients with Calcification Fare Worse After TAVR, But Device Type Matters

Michael O'Riordan

May 17, 2017

REPRISE III: Lotus Valve Matches CoreValve in First Head-to-Head TAVR Trial

News Conference News EuroPCR 2017

REPRISE III: Lotus Valve Matches CoreValve in First, Large Head-to-Head TAVR Trial

Shelley Wood

May 16, 2017

News Daily News

Updated PARTNER 2 Valve-in-Valve Registry: More Experience, Better Outcomes

Shelley Wood

May 02, 2017

News Daily News

Balloon Predilation Not Mandatory Before TAVR, Meta-analysis Suggests

Caitlin E. Cox

April 21, 2017

News Daily News

Permanent Pacemakers After TAVR: Model Helps Predict Individual Patient Risk With Sapien 3

L.A. McKeown

April 12, 2017

Presentation

A Highly Predictive Risk Model for New Permanent Pacemaker Implantation After Sapien 3 TAVR

April 12, 2017

News Conference News ACC 2017

TAVR for Bicuspid Aortic Stenosis? Registry Offers Clues to Safety, Outcomes

Shelley Wood

March 24, 2017

News Daily News

FDA Approves Next-Gen CoreValve Evolut PRO Valve

Todd Neale

March 22, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Three

Shelley Wood

March 19, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day One

Shelley Wood

March 17, 2017

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Todd Neale

March 17, 2017

Presentation SIF 2017

Best Practices: Sapien 3

Presenter: Samir Kapadia

March 11, 2017

News Conference News CRT 2017

Lotus TAVR Device With Depth Guard Reduces Risk of Pacemaker Implantation

Michael O'Riordan

February 22, 2017

News Daily News

Early Clinical Outcomes With Evolut R Reassure, Suggest Improvements Over First-Gen CoreValve

Michael O'Riordan

February 09, 2017

News Conference News ISET 2017

Forging Into the Future: Debating the Merits of TAVR in Younger, Futile, and Lower-Risk Patients

Caitlin E. Cox

February 06, 2017

Advertisement

TAVR Use Triples in France, With Docs Treating Lower-Risk Patients

Merits of Minimalist TAVR: Patient Satisfaction and a Better Bottom Line

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Q&A: Transcatheter Valve Innovation Past, Present, and Future as TVT Turns 10

TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years

Bicuspid AS Patients with Calcification Fare Worse After TAVR, But Device Type Matters

REPRISE III: Lotus Valve Matches CoreValve in First, Large Head-to-Head TAVR Trial

Updated PARTNER 2 Valve-in-Valve Registry: More Experience, Better Outcomes

Balloon Predilation Not Mandatory Before TAVR, Meta-analysis Suggests

Permanent Pacemakers After TAVR: Model Helps Predict Individual Patient Risk With Sapien 3

A Highly Predictive Risk Model for New Permanent Pacemaker Implantation After Sapien 3 TAVR

TAVR for Bicuspid Aortic Stenosis? Registry Offers Clues to Safety, Outcomes

FDA Approves Next-Gen CoreValve Evolut PRO Valve

Live From Washington: ACC 2017, Day Three

Live From Washington: ACC 2017, Day One

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Best Practices: Sapien 3

Lotus TAVR Device With Depth Guard Reduces Risk of Pacemaker Implantation

Early Clinical Outcomes With Evolut R Reassure, Suggest Improvements Over First-Gen CoreValve

Forging Into the Future: Debating the Merits of TAVR in Younger, Futile, and Lower-Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content